Crossmark

Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2024.100329

Published Print: 2024-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Chen, Yufang https://orcid.org/0009-0009-5924-0600
Ma, Jian https://orcid.org/0009-0006-9589-1943
Gao, Qianqian https://orcid.org/0009-0009-4927-011X
Gai, Yu https://orcid.org/0009-0004-9856-5866
Sun, Yichi https://orcid.org/0009-0007-3537-4992
Wang, Meihua https://orcid.org/0009-0000-0485-0430
License Information

Text and Data Mining valid from 2024-01-01

Text and Data Mining valid from 2024-01-01

Version of Record valid from 2024-01-16
More Information

This article is maintained by: Elsevier

Article Title: Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2024.100329

Content Type: article

Copyright: © 2024 HCFMUSP. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below